Adela, Inc. Information

Adela is developing best-in-class technology to accelerate the diagnosis and improve the management of cancer through blood tests for minimal residual disease (MRD) monitoring and multi-cancer early detection (MCED). Adela’s approach efficiently captures extensive, biologically-relevant genomic information from the methylome, providing greater opportunity to detect cancer signals in the blood compared to platforms that target a smaller set of genomic regions. Adela’s blood-based, tissue-free product ensures universal accessibility to MRD testing for patients with cancer, eliminating any dependency on tumor tissue availability. Our test is clinically validated for two applications: predicting and surveilling for recurrence in patients with head & neck cancer (published in Annals of Oncology) and immunotherapy response monitoring in patients with advanced cancer (published in npj Precision Oncology).